DEUTSCHE BANK AG\ - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$210,337
-19.1%
4,634
+0.0%
0.00%
Q2 2023$260,040
-31.5%
4,632
-44.8%
0.00%
Q1 2023$379,524
+100.1%
8,391
+79.8%
0.00%
Q4 2022$189,714
+287.2%
4,667
+528.1%
0.00%
Q3 2022$49,000
-99.3%
743
-99.4%
0.00%
-100.0%
Q2 2022$7,529,000
-3.4%
123,892
-0.2%
0.00%0.0%
Q1 2022$7,790,000
+3854.3%
124,090
+4663.5%
0.00%
Q4 2021$197,000
-40.5%
2,605
-11.8%
0.00%
Q3 2021$331,000
-51.5%
2,954
-30.0%
0.00%
Q2 2021$683,000
-92.9%
4,217
-94.6%
0.00%
-100.0%
Q1 2021$9,575,000
-61.2%
78,582
-51.3%
0.01%
-66.7%
Q4 2020$24,692,000
+450.9%
161,266
+201.0%
0.02%
+400.0%
Q3 2020$4,482,000
+3.2%
53,585
-9.3%
0.00%0.0%
Q2 2020$4,344,000
+3241.5%
59,103
+1833.4%
0.00%
Q1 2020$130,000
-98.4%
3,057
-97.7%
0.00%
-100.0%
Q4 2019$8,169,000
+440.3%
134,140
+263.6%
0.01%
+400.0%
Q3 2019$1,512,000
+7100.0%
36,896
+7651.3%
0.00%
Q2 2019$21,000
+31.2%
476
+1.9%
0.00%
Q1 2019$16,000
-89.3%
467
-91.2%
0.00%
Q4 2018$150,000
-50.5%
5,285
-22.7%
0.00%
Q3 2018$303,000
-98.4%
6,840
-97.8%
0.00%
-100.0%
Q2 2018$18,673,000
+1574.7%
317,820
+1200.7%
0.01%
+400.0%
Q1 2018$1,115,000
-18.4%
24,435
-58.1%
0.00%0.0%
Q4 2017$1,367,000
+170.2%
58,265
+105.3%
0.00%
Q3 2017$506,000
+6225.0%
28,384
+5576.8%
0.00%
Q2 2017$8,000
-94.7%
500
-92.8%
0.00%
Q1 2017$150,0006,9000.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2018
NameSharesValueWeighting ↓
Versant Venture Management, LLC 508,558$82,330,00027.28%
Valiant Capital Management, L.P. 307,700$49,814,0003.74%
NEA Management Company, LLC 1,590,002$257,405,0003.35%
NIA IMPACT ADVISORS, LLC 39,891$6,458,0003.15%
Ikarian Capital, LLC 200,000$32,379,0002.62%
Soleus Capital Management, L.P. 103,114$16,693,0002.57%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 157,334$25,471,0002.47%
Capital Impact Advisors, LLC 45,440$7,356,0002.37%
ARK Investment Management 7,776,119$1,258,876,0002.34%
Sassicaia Capital Advisers LLC 13,513$2,188,0002.28%
View complete list of CRISPR THERAPEUTICS AG shareholders